Pfizer prevails in COX-2 patent case
A University of Rochester patent claiming the use of COX-2 inhibitors to treat inflammation is invalid because it failed to identify the compounds claimed, a federal appeals court says in a 1ruling for Pfizer. The university sued Pfizer in 2000, alleging that the sale of the COX-2 inhibitors Celebrex (celecoxib) and Bextra (valdecoxib) infringed the patent (2"The Pink Sheet" April 17, 2000, p. 14)...
You may also be interested in...
Pharmacia is preparing to defend itself against a COX-2 inhibitor patent infringement suit brought by the University of Rochester rather than agreeing to pay royalties to the university.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.